Developer docs
API playgroundTry for free, no card

Search company profiles

Immortal Dragons

Full company profile

uuid0007ic5

Namestring
Immortal Dragons
Legal namestring
Immortal Dragons
Websiteurl
id.life
Company typeenum
Private
Founded yearint
2015
Descriptiontext

Immortal Dragons is a privately held, purpose-driven longevity investment fund headquartered in Biopolis, Singapore, founded by Boyang Wang. The firm operates a $40 million fund dedicated to radical life-extension technologies, guided by a 'Replace Not Repair' thesis that prioritizes organ replacement, 3D bioprinting, gene therapy, and artificial womb approaches over incremental repair-oriented therapeutics. Its disclosed portfolio is concentrated in four early-stage biotechs: R3 Bio (US-based, developing non-sentient 'bodyoid' organ sacks alongside Tim Draper and LongGame Ventures), Unlimited Bio (dual AAV9-Follistatin + VEGF plasmid gene therapy with a registered Phase 1/2a trial in Honduras' Próspera ZEDE), Frontier Bio (3D biofabrication of vascular and organ-scale tissue), and Etheros Pharmaceuticals (water-soluble fullerene-based catalytic antioxidants based in Singapore).

The fund's competitive positioning is built on Singapore's regulatory environment, which it leverages to source and support exploratory biomedical research that faces higher barriers in Western jurisdictions. Beyond direct investment, Immortal Dragons operates an active ecosystem-buildout program: it produces two podcast series (Immortal Dragons and Long Talk), translates and publishes longevity-related books, sponsors industry conferences and academic institutions, and maintains a presence across YouTube, LinkedIn, Spotify, Bilibili, Xiaohongshu, and WeChat to reach both English- and Chinese-speaking longevity audiences. The firm distributes capital exclusively through direct private investment rounds into portfolio companies; it does not sell products or services, and there is no disclosed pricing, fee schedule, or revenue figure.

Financially, Immortal Dragons remains early-stage. The fund vehicle was formally launched in July 2025 and is actively deploying across at least four portfolio companies, with founder Boyang Wang serving as the principal public face — including a Financial Times Tech Tonic podcast appearance in early 2026 and recurring thought-leadership contributions to Cell & Gene, Longevity.Technology, and the U.S. Transhumanist Party. Headcount and revenue are not publicly disclosed, and the firm's economics are those of a sub-$50M emerging fund: management fees only, no realized carry, and key-person concentration around the founder.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSingapore, Singapore
HQ citystring
Singapore
HQ countrystring
Singapore
HQ regionstring
Asia
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
longevity investment fund, biotech venture capital, life extension research, regenerative medicine investment, anti-aging biotech funding
Industry2 codes
PRIMARYFSANAJAN
SDG / Thematic Sustainable Investment Funds
Financial & Insurance/Private Equity & Venture Capital/Impact / ESG & Sustainable Investment Funds
SECONDARYFSAAALAB
Sustainable/Thematic Investing (Climate, Clean Tech, Water, Biodiversity)
Financial & Insurance/Asset & Wealth Management/Asset Management — ESG/Sustainable & Impact Investing
NAICS code2 codes
  • Funds, Trusts, and Other Financial Vehicles525
  • Other Investment Pools and Funds5259
SIC code1 code
  • Investment Advice6282
Product category
Longevity Venture Capital
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Fund Management / Investment Returns
TypeLicensing Royalties
Description

As a $40 million longevity investment fund, Immortal Dragons generates returns through equity investments in biotech companies developing longevity technologies. The fund takes equity stakes in portfolio companies including R3 Bio, Unlimited Bio, Frontier Bio, and Etheros Pharmaceuticals.

id.life
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Operations, Marketing or Sales, Technology or R&D
Pricing details1 tier
1Fund management - $40 million longevity fund
ModelOtherBilling cadenceMulti-year contract
Notes

Immortal Dragons operates as a $40 million longevity fund. Specific fund management fees, carry structures, and investment minimums are not publicly disclosed.

id.life
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 2 records shown
1不朽真龙 Immortal Dragons (Podcast)
Description

The company's main podcast series covering longevity science, featuring expert interviews, translations of international longevity research, and discussions on aging and life extension.

id.life
+1 more record
Core offering1 text field

Immortal Dragons is a purpose-driven longevity investment fund based in Singapore that deploys capital into biotech companies developing radical life-extension technologies. The fund targets breakthrough areas mainstream investors avoid, including organ replacement, 3D bioprinting, gene therapies, and artificial womb research, with a portfolio spanning xenotransplantation and regenerative medicine.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Fund invests in companies addressing organ transplant market exceeding $12 billion annually (Frontier Bio)
+1 more record
Product overview1 text field

Immortal Dragons is a purpose-driven longevity investment fund headquartered in Biopolis, Singapore. The fund focuses on investing in breakthrough longevity technologies including organ replacement strategies, 3D bioprinting, gene therapy, and artificial wombs. Beyond investments, the organization supports longevity science through publishing translated books, funding industry conferences and academic institutions, and producing podcasts and media content to promote anti-aging research and longevity concepts.

Product and service2 records
1Immortal Dragons $40 Million Longevity Investment Fund
CategoryVenture Capital Fund
2Immortal Dragons Podcast (不朽真龙 Podcast)
Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
1Jean Hébert / ARPA-H
Strategic tierMinorTypeStrategic or Co-development Partner
Description

R3 Bio's founder John Schloendorn has an informal collaboration with Jean Hébert, a program manager at ARPA-H (Advanced Research Projects Agency for Health), on body replacement technology. ARPA-H is a U.S. government agency funding health research.

technologyreview.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

US-based venture fund with explicit focus on longevity, AI, and exponential technologies. Direct peer as a thesis-driven fund backing transformative life-extension and biotech ventures.

TypeDirect peer
Description

Laura Deming's venture fund focused on early-stage longevity biotech, one of the pioneering longevity VCs. Directly comparable as a specialist, thesis-driven fund investing in companies extending human healthspan and lifespan.

TypeBroad incumbent
Description

Saudi Arabia-backed foundation deploying over $1B annually into geroscience and longevity research. Broad incumbent as a much larger, well-capitalized player operating in the same longevity investment universe.

TypeDirect peer
Description

German longevity-focused VC fund (part of the Forever Healthy Foundation) backing rejuvenation biotech startups. Direct peer as a thematic longevity fund pursuing similar 'repair the damage' / replacement-style theses.

TypeDirect peer
Description

Hong Kong-based family office/biotech investor (Christian Angermayer) focused on longevity and psychedelic medicine. Direct peer as an Asia-anchored thematic investor in radical longevity ventures.

TypeDirect peer
Description

Public-markets-facing longevity biotech company and investor building a portfolio of therapeutic assets targeting aging. Directly comparable as a dedicated longevity investor with both fund-style and operating-company exposure.

TypeEmerging player
Description

Decentralized autonomous organization funding early-stage longevity research via community-governed token treasury. Emerging peer because while structure differs, the mandate (funding radical longevity science ignored by mainstream capital) is highly analogous.

TypeEmerging player
Description

Non-profit-backed longevity investment vehicle funding tissue engineering and organ replacement startups. Emerging peer as a mission-aligned capital provider in the same radical-replacement thesis space.

TypeDirect peer
Description

Longevity-focused venture fund investing in early-stage biotech companies targeting aging mechanisms. Direct peer in the small, specialized niche of longevity VC.

TypeDirect peer
Description

Sergey Young's $100M longevity-focused venture fund backing healthspan and life-extension technologies. Most directly comparable to Immortal Dragons as a thematic, purpose-driven VC fund targeting radical longevity outcomes.

Market position
Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment6 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Immortal Dragons

Longevity Venture Capitalid.life

What Immortal Dragons does

Immortal Dragons is a privately held, purpose-driven longevity investment fund headquartered in Biopolis, Singapore, founded by Boyang Wang. The firm operates a $40 million fund dedicated to radical life-extension technologies, guided by a 'Replace Not Repair' thesis that prioritizes organ replacement, 3D bioprinting, gene therapy, and artificial womb approaches over incremental repair-oriented therapeutics. Its disclosed portfolio is concentrated in four early-stage biotechs: R3 Bio (US-based, developing non-sentient 'bodyoid' organ sacks alongside Tim Draper and LongGame Ventures), Unlimited Bio (dual AAV9-Follistatin + VEGF plasmid gene therapy with a registered Phase 1/2a trial in Honduras' Próspera ZEDE), Frontier Bio (3D biofabrication of vascular and organ-scale tissue), and Etheros Pharmaceuticals (water-soluble fullerene-based catalytic antioxidants based in Singapore).

The fund's competitive positioning is built on Singapore's regulatory environment, which it leverages to source and support exploratory biomedical research that faces higher barriers in Western jurisdictions. Beyond direct investment, Immortal Dragons operates an active ecosystem-buildout program: it produces two podcast series (Immortal Dragons and Long Talk), translates and publishes longevity-related books, sponsors industry conferences and academic institutions, and maintains a presence across YouTube, LinkedIn, Spotify, Bilibili, Xiaohongshu, and WeChat to reach both English- and Chinese-speaking longevity audiences. The firm distributes capital exclusively through direct private investment rounds into portfolio companies; it does not sell products or services, and there is no disclosed pricing, fee schedule, or revenue figure.

Financially, Immortal Dragons remains early-stage. The fund vehicle was formally launched in July 2025 and is actively deploying across at least four portfolio companies, with founder Boyang Wang serving as the principal public face — including a Financial Times Tech Tonic podcast appearance in early 2026 and recurring thought-leadership contributions to Cell & Gene, Longevity.Technology, and the U.S. Transhumanist Party. Headcount and revenue are not publicly disclosed, and the firm's economics are those of a sub-$50M emerging fund: management fees only, no realized carry, and key-person concentration around the founder.

Immortal Dragons firmographics

Firmographics
Name
Immortal Dragons
Legal name
Immortal Dragons
Website
https://id.life
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
1–10 employees
Ownership category
akta.pro rank

Immortal Dragons industry classification

Industry
Product category
Longevity Venture Capital
NAICS
Funds, Trusts, and Other Financial Vehicles (525), Other Investment Pools and Funds (5259)
SIC
Investment Advice (6282)
akta.pro industry
PRIMARYFSANAJAN
SDG / Thematic Sustainable Investment Funds
Financial & Insurance/Private Equity & Venture Capital/Impact / ESG & Sustainable Investment Funds
SECONDARYFSAAALAB
Sustainable/Thematic Investing (Climate, Clean Tech, Water, Biodiversity)
Financial & Insurance/Asset & Wealth Management/Asset Management — ESG/Sustainable & Impact Investing

Keywords

  • Longevity investment fund
  • Biotech venture capital
  • Life extension research
  • Regenerative medicine investment
  • Anti-aging biotech funding

Where Immortal Dragons is headquartered

Location

Headquarters

HQ city
Singapore
HQ country
Singapore
HQ region
Asia

Offices2 records

Markets served

Immortal Dragons business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D

Revenue model

  1. Fund Management / Investment Returns: As a $40 million longevity investment fund, Immortal Dragons generates returns through equity investments in biotech companies developing longevity technologies. The fund takes equity stakes in portfolio companies including R3 Bio, Unlimited Bio, Frontier Bio, and Etheros Pharmaceuticals.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractFund management - $40 million longevity fund

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Immortal Dragons product offering

Product offering

Core offering

Immortal Dragons is a purpose-driven longevity investment fund based in Singapore that deploys capital into biotech companies developing radical life-extension technologies. The fund targets breakthrough areas mainstream investors avoid, including organ replacement, 3D bioprinting, gene therapies, and artificial womb research, with a portfolio spanning xenotransplantation and regenerative medicine.

Product overview

Immortal Dragons is a purpose-driven longevity investment fund headquartered in Biopolis, Singapore. The fund focuses on investing in breakthrough longevity technologies including organ replacement strategies, 3D bioprinting, gene therapy, and artificial wombs. Beyond investments, the organization supports longevity science through publishing translated books, funding industry conferences and academic institutions, and producing podcasts and media content to promote anti-aging research and longevity concepts.

Differentiator

Problem solved

Functional benefit

Brands

  • 不朽真龙 Immortal Dragons (Podcast): The company's main podcast series covering longevity science, featuring expert interviews, translations of international longevity research, and discussions on aging and life extension.
  • 龙门阵 Long Talk

Products and services

  • Immortal Dragons $40 Million Longevity Investment Fund
  • Immortal Dragons Podcast (不朽真龙 Podcast)

Quantifiable outcome

  • Fund invests in companies addressing organ transplant market exceeding $12 billion annually (Frontier Bio)
  • +1 more outcomes

Companies that use Immortal Dragons

Customer profile

Named customers4 records

Segments1 record

Ideal customer profiles1 record

Immortal Dragons technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Immortal Dragons partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Jean Hébert / ARPA-HminorStrategic or Co-development PartnerR3 Bio's founder John Schloendorn has an informal collaboration with Jean Hébert, a program manager at ARPA-H (Advanced Research Projects Agency for Health), on body replacement technology. ARPA-H is a U.S. government agency funding health research.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Immortal Dragons competitors and assessment

Company assessment

Direct peers

  • BOLD Capital Partners: US-based venture fund with explicit focus on longevity, AI, and exponential technologies. Direct peer as a thesis-driven fund backing transformative life-extension and biotech ventures.
  • The Longevity Fund: Laura Deming's venture fund focused on early-stage longevity biotech, one of the pioneering longevity VCs. Directly comparable as a specialist, thesis-driven fund investing in companies extending human healthspan and lifespan.
  • Kizoo Technology Ventures: German longevity-focused VC fund (part of the Forever Healthy Foundation) backing rejuvenation biotech startups. Direct peer as a thematic longevity fund pursuing similar 'repair the damage' / replacement-style theses.
  • Apeiron Investment Group: Hong Kong-based family office/biotech investor (Christian Angermayer) focused on longevity and psychedelic medicine. Direct peer as an Asia-anchored thematic investor in radical longevity ventures.
  • Juvenescence: Public-markets-facing longevity biotech company and investor building a portfolio of therapeutic assets targeting aging. Directly comparable as a dedicated longevity investor with both fund-style and operating-company exposure.
  • Formic Ventures: Longevity-focused venture fund investing in early-stage biotech companies targeting aging mechanisms. Direct peer in the small, specialized niche of longevity VC.
  • Longevity Vision Fund: Sergey Young's $100M longevity-focused venture fund backing healthspan and life-extension technologies. Most directly comparable to Immortal Dragons as a thematic, purpose-driven VC fund targeting radical longevity outcomes.

Broad incumbents

  • Hevolution Foundation: Saudi Arabia-backed foundation deploying over $1B annually into geroscience and longevity research. Broad incumbent as a much larger, well-capitalized player operating in the same longevity investment universe.

Emerging players

  • VitaDAO: Decentralized autonomous organization funding early-stage longevity research via community-governed token treasury. Emerging peer because while structure differs, the mandate (funding radical longevity science ignored by mainstream capital) is highly analogous.
  • Methuselah Fund: Non-profit-backed longevity investment vehicle funding tissue engineering and organ replacement startups. Emerging peer as a mission-aligned capital provider in the same radical-replacement thesis space.

Market position

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Immortal Dragons social profiles

Digital presence

Immortal Dragons financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Immortal Dragons leadership team

Management profile

Number of profiles

Profiles1 record

Immortal Dragons funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Immortal Dragons M&A and investment

M&A and investment

M&A

Investments6 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Immortal Dragons

What does Immortal Dragons do?

Immortal Dragons is a purpose-driven longevity investment fund based in Singapore that deploys capital into biotech companies developing radical life-extension technologies. The fund targets breakthrough areas mainstream investors avoid, including organ replacement, 3D bioprinting, gene therapies, and artificial womb research, with a portfolio spanning xenotransplantation and regenerative medicine.

Is Immortal Dragons a public or private company?

Immortal Dragons is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Immortal Dragons founded?

Immortal Dragons was founded in 2015. It employs 1 to 10 people.

Where is Immortal Dragons based?

Immortal Dragons is headquartered in Singapore, Singapore, in the Asia region.

How does Immortal Dragons make money?

One revenue line is on record: fund Management / Investment Returns.

Who are Immortal Dragons's main competitors?

Direct peers on record are BOLD Capital Partners, The Longevity Fund, Kizoo Technology Ventures, Apeiron Investment Group, Juvenescence, Formic Ventures and Longevity Vision Fund. Hevolution Foundation is listed as a broad incumbent. Emerging players are VitaDAO and Methuselah Fund.

Does Immortal Dragons have an API?

No public API is recorded for Immortal Dragons.

What industry is Immortal Dragons in?

Immortal Dragons's product category is Longevity Venture Capital. Its primary akta.pro industry code is FSANAJAN, SDG / Thematic Sustainable Investment Funds, with a secondary code of FSAAALAB, Sustainable/Thematic Investing (Climate, Clean Tech, Water, Biodiversity). Its NAICS code is 525 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Longevity.TechnologyLongevity fund Immortal Dragons invests in stem cell startup Renewal BioImmortal Dragons invested $40 million in Renewal Bio, an Israeli regenerative medicine company. The fund backs Renewal Bio's Stembroid platform, which produces patient-matched stem cells from skin or blood cells. The company claims the platform enables natural developmental cues to form 3D models without sperm or eggs.FinancialContent Business PageImmortal Dragons Backs Renewal Bio to Grow Patient-Matched Cell PlatformImmortal Dragons, a $40 million longevity fund, invested in Renewal Bio, an Israeli regenerative medicine company developing patient-matched cells. Renewal Bio's Stembroid platform uses natural developmental cues to produce cells from reprogrammed skin or blood cells, aiming to eliminate donor-matching needs. The investment supports Renewal Bio's work to address cell supply as a bottleneck for tissue replacement.NewswireImmortal Dragons Backs Renewal Bio to Grow Patient-Matched Cell PlatformImmortal Dragons, a $40 million longevity fund, invested in Renewal Bio, an Israeli regenerative medicine company developing patient-matched human cells. Renewal Bio's Stembroid platform uses natural developmental cues to produce cells from reprogrammed skin or blood cells, aiming to eliminate donor-matching needs. The investment supports Renewal Bio's work to address cell supply as a bottleneck for tissue replacement.FinanzNachrichten.deImmortal Dragons Backs Renewal Bio to Grow Patient-Matched Cell PlatformImmortal Dragons, a $40 million longevity fund, invested in Renewal Bio, an Israeli regenerative medicine company developing patient-matched cells. Renewal Bio's Stembroid platform uses natural developmental cues to produce cells from reprogrammed skin or blood cells, aiming to eliminate donor-matching needs. The investment supports Renewal Bio's exclusive license from the Weizmann Institute.MorningstarImmortal Dragons Backs Renewal Bio to Grow Patient-Matched Cell PlatformImmortal Dragons, a $40 million longevity fund, invested in Renewal Bio, an Israeli regenerative medicine company developing patient-matched cells. Renewal Bio's Stembroid platform uses natural developmental cues to produce cells without donors, addressing transplant supply bottlenecks. The investment supports Renewal Bio's work to remove cell supply as a barrier to tissue replacement.Pulse 2.0Immortal Dragons: Interview With Founder And CEO Boyang Wang About Longevity Investing And Biological ReplacementBoyang Wang, founder and CEO of Immortal Dragons, discussed the $40 million Singapore-based longevity fund's focus on biological replacement, gene therapy, and brain rejuvenation. The fund's thesis shifted from broad longevity to replacement strategies, citing Frontier Bio's FDA-approved vascular graft and pig kidney xenotransplantation. Wang highlighted regulatory progress, such as New Hampshire's HB701, as a sign of mainstream acceptance.pharmaphorumThe frontier of 3D biofabrication in the race for healthy longevityImmortal Dragons has made a strategic investment in Frontier Bio, a biotechnology company specializing in 3D biofabrication technologies for tissue engineering and organ replacement. The partnership aims to advance radical life extension solutions, specifically targeting organ failure by developing functional blood vessels and lab-grown organs that integrate with human tissue.FinanzNachrichten.deImmortal Dragons: Sundial Initiative Advisor Boyang Wang Sponsors Nakauchi Lab's Work on "Bodyoids"Boyang Wang, advisor to the Sundial Initiative and founder and CEO of the longevity fund Immortal Dragons, has sponsored the Nakauchi Lab's research on bodyoids — human bodies grown from pluripotent stem cells as a potential solution to organ transplant shortages and drug testing limitations. The concept, detailed in MIT Technology Review, proposes growing immunologically matched organs and providing human test substrates to address the more than 100,000 US patients awaiting transplants and the fewer than 15% of drugs reaching approval due to poor animal model proxies. Wang stated the sponsorship aligns with Immortal Dragons' investment thesis focused on replacement technologies, arguing that funding such underfunded research early is critical to advancing breakthroughs the world urgently needs.FinancialContent Business PageSundial Initiative Advisor Boyang Wang Sponsors Nakauchi Lab's Work on "Bodyoids"Boyang Wang, founder and CEO of the longevity fund Immortal Dragons, has sponsored the Nakauchi Lab's research on bodyoids—human bodies grown from pluripotent stem cells as a potential solution to organ transplant scarcity and drug testing limitations. The sponsorship aligns with Immortal Dragons' investment thesis focused on replacement technologies in longevity, with Wang citing the global organ shortage as a key motivation for supporting early-stage scientific work. The fund, headquartered in Singapore, has made multiple research commitments in aging and neurodegeneration, including support for the Tony Wyss-Coray Lab.Gadgets 360Silicon Valley Startup Wants To Grow 'Headless Humans' To Replace Animal TestingSilicon Valley biotech startup R3 Bio is developing non-sentient, brainless human body constructs called 'organ sacks' or 'bodyoids' as platforms to replace animal testing in drug research, backed by investors including Tim Draper and Singapore-based Immortal Dragons. The company has successfully created organ sacks in mice and plans to expand to monkeys and eventually human cells, arguing the technology could make testing more scalable and ethical. Scientific experts have questioned both the safety and utility of the approach, with Harvard's George Church calling it 'not very useful, in addition to being repulsive.'